Allopurinol is the medicine used in cases where too much uric acid is produced, which can lead to excessive levels in the blood or hyperuricemia. This may include gout or kidney stones (renal calculi), certain types of kidney diseases or cancer patients.
Allopurinol (Dosage)
Allopurinol works by inhibiting the enzyme xanthine oxidase, which is responsible for converting purines into uric acid. Allopurinol prevents gout attacks and the formation of urate crystals in tissues and joints.
The dose of allopurinol varies depending on the severity of the condition, kidney function, and the patient's response to treatment. Generally, treatment begins with low doses (100 mg/day for people with normal kidney function) that are gradually increased until adequate control of uric acid levels is achieved.
SIDE EFFECTS
- Skin rashes
- Gastrointestinal discomfort (nausea, diarrhea)
- Dizziness or drowsiness
PRECAUTIONS
Exceptionally, allopurinol may cause severe allergic reactions such as hypersensitivity syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Severe reactions include fever, skin rash, blisters and peeling of the skin, joint pain, and abnormalities in blood and liver function tests. Patients with the HLA-B*5801 allele, not evaluated here, have a higher probability of suffering adverse reactions. This allele is more common in Asian populations, although it may also be present in Caucasians.
PHARMACOLOGICAL INTERACTIONS
Allopurinol can interact with other medications, enhancing the toxicity of certain immunosuppressants (azathioprine, cyclosporine, and mercaptopurine) and increasing the effect of coumarin anticoagulants and the bronchodilator theophylline. Allopurinol may increase the risk of skin reactions if administered together with certain antibiotics such as ampicillin/amoxicillin. Allopurinol elimination increases with concomitant administration of probenecid, benzbromarone, sulfinpyrazone, or high doses of salicylates.
BRAND NAMES
- Aloprim®
- Urosin®
- Zyloric®
- Zyloprim®
Genes analyzed
Bibliography
Eckenstaler R, Benndorf RA. The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update. Int J Mol Sci. 2021 Jun 22;22(13):6678.
van der Pol KH, Nijenhuis M, Soree B, et al. Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate. Eur J Hum Genet. 2024 Feb;32(2):155-162.
Wallace MC, Roberts RL, Nanavati P, et al. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology (Oxford). 2018 Apr 1;57(4):656-660.
Wen CC, Yee SW, Liang X, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015 May;97(5):518-25.
Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10338-42.
White WB, Saag KG, Becker MA, et al.Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29;378(13):1200-1210.
